Get the Stockscreener App
2.28
35.77%
-1.27
After Hours:
2.34
0.06
+2.63%
Black Diamond Therapeutics Inc stock is traded at $2.28, with a volume of 8.33M.
It is down -35.77% in the last 24 hours and down -31.94% over the past month.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
See More
Previous Close:
$3.55
Open:
$3.01
24h Volume:
8.33M
Relative Volume:
7.89
Market Cap:
$130.65M
Revenue:
$70.00M
Net Income/Loss:
$22.37M
P/E Ratio:
5.9937
EPS:
0.3804
Net Cash Flow:
$29.61M
1W Performance:
-17.09%
1M Performance:
-31.94%
6M Performance:
-40.00%
1Y Performance:
+10.68%
1-Day Range:
$2.25
$3.0742
1-Week Range:
$2.25
$3.97
52-Week Range:
$1.93
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.28 | 203.42M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-25 | Resumed | Piper Sandler | Overweight |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Black Diamond Therapeutics lung cancer drug shows 15.2-month PFS in phase 2 study - MSN
Black Diamond Therapeutics (BDTX) Shares Tumble Nearly 35% on Clinical SetbackExpert Trade Signals - Newser
Stifel reiterates Black Diamond Therapeutics stock rating at Buy By Investing.com - Investing.com Canada
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - The Manila Times
BDTX Stock Price, Quote & Chart | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Black Diamond Therapeutics Reports Positive Phase 2 Results for Silevertinib in Frontline NSCLC With EGFR Non-Classical Mutations, Highlighting Strong CNS Activity and mPFS of 15.2 Months 13 - Minichart
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data - TipRanks
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study - Yahoo Finance
Black Diamond reports silevertinib trial results in lung cancer By Investing.com - Investing.com Australia
Black Diamond reports silevertinib trial results in lung cancer - Investing.com
Black Diamond Therapeutics Announces Encouraging Phase 2 Trial Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - Quiver Quantitative
Positive NSCLC trial results boost Black Diamond (NASDAQ: BDTX) drug hopes - Stock Titan
Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire
Lung cancer trial: silevertinib shows 86% brain response, 60% tumor response - Stock Titan
BDTX shares gain 11% in a week: Here's what you should know - MSN
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX - RTTNews
BDTX Technical Analysis | Trend, Signals & Chart Patterns | BLACK DIAMOND THERAPEUTICS I (NASDAQ:BDTX) - ChartMill
Black Diamond to present phase 2 silevertinib trial data Thursday By Investing.com - Investing.com South Africa
Black Diamond to present phase 2 silevertinib trial data Thursday - Investing.com
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - The Manila Times
Black Diamond Therapeutics to Host Webcast for Investors - GlobeNewswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TradingKey - TradingKey
Black Diamond Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BDTX Shares Gain 11% in a Week: Here's What You Should Know - TradingView
Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Black Diamond Therapeutics (NASDAQ:BDTX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Black Diamond Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond: Q1 Earnings Snapshot - marketscreener.com
Black Diamond starts GBM Phase 2 dosing as ASCO lung data nears - Stock Titan
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
Black Diamond Therapeutics (NASDAQ: BDTX) swings to Q1 2026 loss as Servier upfront drops out - Stock Titan
Black Diamond Therapeutics (Nasdaq: BDTX) swings to Q1 loss as silevertinib trials advance - Stock Titan
MSN Money - MSN
Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday - MarketBeat
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
BDTX - Finviz
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):